Press Release 

T-CURX acquires Pantherna Therapeutics to leverage the complementary expertises and proprietary technologies of both companies to accelerate clinical translation of CAR-T strategies with a clear focus on clinical validation of in vivo CAR-T therapies.

• T-CURX leverages Pantherna’s deep expertise and proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier 
• T-CURX’ proprietary and clinically validated transposon-based non-viral CAR-T technology is potentiated and de-risked by Pantherna’s proprietary PTXmRNA® and PTXΔLNP® platforms, enabling the expansion of in vivo CAR-T therapies beyond cancer indications 
• T-CURX’ acquisition of Pantherna builds on a successful prior technology collaboration and preclinical validation of their combined technologies 

June 1, 2026. Today, leading CAR-T company T-CURX announces the signing of a definitive agreement for the acquisition of Pantherna Therapeutics, a German biotechnology company specializing in mRNA engineering and lipid nanoparticle (LNP) delivery technologies. Pantherna will continue to operate as Pantherna Therapeutics  as a wholly owned subsidiary of T-CURX. The complementary expertises and proprietary technologies of both companies will be leveraged to accelerate clinical translation of CAR-T strategies with a clear focus on clinical validation of in vivo CAR-T therapies. T-CURX is a Würzburg-headquartered private biotech company with an additional site in Munich with strong expertise, proprietary technologies and track record for clinical translation of non-viral, transposon-based CAR-T therapies for novel and differentiated targets. T-CURX is backed by private investors and an international syndicate of blue-chip Biotech investors led by Swiss BiomedVC. T-CURX closed a USD 20.5 million Series A financing round at the end of 2025. Pantherna was supported by a group of private investors and Germany-based High-Tech Gründerfonds (HTGF), who will become new shareholders of T-CURX. Financial terms of the transaction are not disclosed. 

“With this acquisition, we are bringing together two highly complementary technology platforms and teams. We are taking a decisive step forward to accelerate the clinical development of differentiated, next-generation in vivo CAR-T therapies,” said Ulf Grawunder, CEO and co-founder of T-CURX. “Our strength in clinical translation of non-viral transposon-based CAR-T therapies combined with Pantherna’s proprietary mRNA and LNP-based delivery capabilities allows us to build an efficient engine to expedite clinical development of differentiated in vivo CAR-T assets in cancer, as well as in other indications.” 

“Joining T-CURX is a natural evolution of our collaboration,” said Ansgar Santel, CEO of Pantherna Therapeutics. “This integration allows us to address both stable and transient cell engineering strategies based on powerful and proven proprietary platforms. We believe this positions us uniquely to efficiently drive CAR-T innovation forward for patients in need, particularly for in vivo CAR-T strategies across a broad range of therapeutic applications.” 

The combination of both companies positions T-CURX to become a leading next-generation CAR-T player, being the first European Biotech with both proprietary CAR-T and LNP-technologies under one roof, allowing integration of key capabilities across the full value chain from discovery to clinical development of CAR-T products. Post acquisition, the company will have a total headcount of 35 and will manage a collective portfolio of currently 16 patent families protecting the combined technologies and assets. 

-end- 

About T-CURX 

T-CURX GmbH is a private, Würzburg & Munich based, German biotech company with a wholly owned subsidiary, Pantherna Therapeutics, in Hennigsdorf & Berlin, Germany, combining next-generation non-viral CAR-T and LNP-nucleic acid vector delivery technologies under one roof. T-CURX is financially backed by a syndicate of international VC investors and family offices from Germany and Switzerland, led by Swiss BiomedVC, with Bayernkapital (Germany), Highlight Capital (China) and i&iBio Fund (Czech Republic) as institutional co-investors. T-CURX has the vision to bring innovative CAR-T cell therapies based on cost-effective and highly scalable non-viral ex vivo and in vivo CAR-T strategies to more cancer patients in need of these effective cancer therapies. T-CURX was spun out of the laboratory of T-CURX’s co-founder Prof. Michael Hudecek at the University of Würzburg and is led by Ulf Grawunder, PhD, a seasoned serial entrepreneur as CEO, who is also one of the co-founders. For more information about T-CURX, visit the company’s website at: www.t-curx.com 

About Pantherna Therapeutics 

Pantherna Therapeutics GmbH, a T-CURX company,  is a biotech company from Hennigsdorf, Germany, with additional operations in Berlin, specializing in mRNA engineering and lipid nanoparticle (LNP) delivery technologies. Its proprietary PTXmRNA® and PTXΔLNP® platforms enable transient, controllable gene expression and targeted in vivo delivery of nucleic acids. Pantherna adds a crucial technology layer for potentiating T-CURX next-generation CAR-T therapies, further advancing ex vivo as well as future in vivo CAR-T strategies in oncology and also additionalindications. For more information about Pantherna Therapeutics, visit the company’s website at www.pantherna-therapeutics.com 

 For further information: 

Ulf Grawunder, PhD, CEO T-CURX 

E-Mail: ulf@t-curx.com 

Ansgar Santel, PhD, CEO Pantherna Therapeutics 

E-Mail: a.santel@pantherna-therapeutics.com 

For media enquiries: 

Phone: +49-(0)-931-250-99-712 

E-mail: pr@t-curx.com 

Der Beitrag T-CURX acquires Pantherna Therapeutics to accelerate clinical translation of its non-viral in vivo CAR-T strategies erschien zuerst auf Pantherna Therapeutics.

Düsseldorf (Germany) / Hennigsdorf (Germany), 11.02.2026

Pantherna Therapeutics, a biotech company enabling innovative mRNA therapies with tissue/-cell-selective LNP formulations, announces a collaboration with the Etzkorn Lab at Heinrich Heine University Düsseldorf (HHU, Institute of Physical Biology) and the Lang lab at University Hospital Düsseldorf (UKD). The research collaboration focuses on exploring the in vivo pharmacological use of Pantherna’s PTXDLNP® formulation technology along with RNA-cleaving DNAzymes developed at HHU/UKD for non-viral delivery of a novel class of therapeutic nucleic acids.

Led by Dr. Manuel Etzkorn, Heisenberg Research Group Leader at the Institute of Physical Biology, the Etzkorn Lab specializes in the structural and functional analysis of membrane systems and nucleic acid interactions in native environments. Dr. Etzkorn’s research is supported by the prestigious Heisenberg Programme of the German Research Foundation (DFG) as well as the Federal Agency for Breakthrough Innovations (SPRIND), highlighting the lab’s excellence in fundamental biophysical research with translational potential.

The clinical and preclinical focus is anchored in the Institute of Molecular Medicine II, led by Prof. Dr. Philipp Lang, a renowned expert in tumour and infection immunology. The institute’s predominant aim is to explore innovative therapeutic strategies. His work describes several mechanisms regulating effective immunity against infections and cancer, which attracted prestigious awards.

The research efforts were additionally boosted by the Volkswagen Stiftung. This collaborative funding makes it possible to engage two leading experts whose contributions are pivotal to the project’s success: Prof. Dr. Holger Gohlke, Director of the Institute of Bio- and Geosciences at Forschungszentrum Jülich, brings world-class expertise in predicting (bio)molecular structures, while Prof. Dr. Stephanie Kath-Schorr provides essential support through advanced chemical synthesis of nucleic acids.

The latest milestone is the approval of the 3 Mio. € Go Bio-next project ‘DNAmazing’, which consolidates the ongoing collaboration with Pantherna to deepen our understanding of lipid nanoparticle (LNP) behaviour and DNAzyme activity. This strengthened partnership is pivotal for translating fundamental research into a new class of nucleic acid therapies targeting viral infections and cancer.

Der Beitrag Pantherna Therapeutics supports the translational research at HHU and UKD Düsseldorf to advance non-viral nucleic acid delivery technologies for catalytic DNAzymes erschien zuerst auf Pantherna Therapeutics.

Turin (Italy) / Hennigsdorf (Germany), 08.01.2026

Kither Biotech S.r.l. and Pantherna Therapeutics GmbH today announced a strategic research collaboration combining Pantherna’s proprietary lipid nanoparticle (LNP) mRNA delivery platform with Kither’s clinical-stage peptide therapeutic KIT2014. The partnership explores synergistic therapeutic approaches where mRNA-based protein restoration and functional enhancement through peptide therapy work in concert to address genetic respiratory diseases.

The collaboration leverages complementary mechanisms: Pantherna’s PTXmRNA® and PTXΔLNP® platforms deliver therapeutic mRNA to restore protein expression, while KIT2014, a dual PDE3/4 inhibitor, enhances protein function through compartmentalized cAMP signaling. This dual-mechanism strategy represents a differentiated approach applicable to genetic lung diseases where both protein replacement and functional optimization may be required for therapeutic efficacy.

“This collaboration validates our mechanism of enhancing protein function through localized cAMP modulation,” said Dr. Dimitrios Goudis, CEO of Kither Biotech. “KIT2014, which holds EMA Orphan Drug Designation, demonstrates multi-factorial effects on airway epithelial function including CFTR potentiation, enhanced epithelial homeostasis, and anti-inflammatory activity. Combining our peptide’s functional enhancement capabilities with Pantherna’s mRNA delivery platform creates complementary therapeutic strategies that could address limitations in current genetic medicine approaches. We see this collaboration opening new strategic opportunities for both standalone and combination development programs.”

“We are excited to partner with Kither Biotech to explore synergistic approaches in genetic lung diseases,” said Dr. Ansgar Santel, CEO of Pantherna Therapeutics. “Our proprietary LNP platform enables efficient delivery of therapeutic mRNA, while Kither’s proven clinical development capabilities combined with KIT2014’s ability to enhance epithelial function through cAMP signaling create powerful complementary capabilities to our mRNA technology.”

Both companies are advancing their respective technology platforms and exploring strategic partnerships to maximize therapeutic applications across multiple respiratory indications. The synergistic approach developed through this collaboration may have broader applicability beyond the initial proof-of-concept studies.

About Kither Biotech S.r.l.

Kither Biotech, headquartered in Turin, Italy, is a clinical-stage pharmaceutical company developing first-in-class inhaled peptide therapeutics for respiratory diseases. The company’s lead asset, KIT2014, is a peptide that modulates airway function through a novel mechanism involving disruption of the PI3Kγ-PKA-PDE complex, leading to compartmentalized cAMP elevation and enhanced CFTR gating, epithelial homeostasis, bronchodilation, and anti-inflammatory effects. Kither is advancing clinical development programs to maximize the therapeutic potential of its pipeline. For partnership inquiries: info@kitherbiotech.com

About Pantherna Therapeutics GmbH

Pantherna Therapeutics, based in Hennigsdorf with research operations in Berlin, Germany, is a biotechnology company developing mRNA-based therapeutics using its proprietary PTXmRNA® and PTXΔLNP® platforms. The company’s advanced lipid nanoparticle technology enables targeted delivery of therapeutic mRNA for genetic and vascular diseases. Pantherna’s platform addresses critical challenges in mRNA delivery, with applications in respiratory and other indications. For further information, feel free to reach out to contact@pantherna-therapeutics.com.

Der Beitrag Kither Biotech and Pantherna Therapeutics Announce Strategic Collaboration on Synergistic mRNA and Peptide Therapies for Genetic Lung Diseases erschien zuerst auf Pantherna Therapeutics.

Hennigsdorf, Germany 

Pantherna Therapeutics GmbH, a leading innovator in advanced LNP technologies for mRNA-based therapeutics, is pleased to announce the upcoming grant of US-Patent application No. 17/173,109, titled “Recombinant Nucleic Acid Construct,”

The forthcoming U.S. patent will further strengthen Pantherna’s global intellectual property position and safeguard its PTXmRNA® technology, which facilitates efficient and enduring protein expression in therapeutic applications. Securing patent protection in the United States, a significant market for mRNA and gene therapy innovation, underscores the broad applicability and pioneering nature of Pantherna’s technology.

Dr. Jörg Kaufmann, Chief Scientific Officer of Pantherna Therapeutics, asserted, “Securing Patent protection in the United States, in conjunction with our existing patents in Canada, Europe, Japan, and Korea, underscores the transformative potential of our PTXmRNA® technology. This recognition enhances our standing as a prospective commercial partner for collaborative research and licensing endeavors in these global markets focused on mRNA-based therapies.”

Der Beitrag Pantherna Therapeutics Secures New Patent Grant in the United States of America erschien zuerst auf Pantherna Therapeutics.

Hennigsdorf, Germany 

Der Beitrag Pantherna Therapeutics GmbH and ARCALIS, Inc. enter research collaboration to expand novel LNP solutions for future mRNA therapeutics erschien zuerst auf Pantherna Therapeutics.

Hennigsdorf, Germany 

Loma Therapeutics and Pantherna Therapeutics are pleased to announce a new collaboration aimed at accelerating the development of next-generation immunotherapies.

This joint initiative brings together Loma’s innovative HPV immunotherapy technology andPantherna’s cutting-edge non-viral Lipid Nanoparticle (LNP) delivery platform. By combining our expertise, Pantherna is proud to support Loma’s mission to develop safer and more effective treatments for HPV-related diseases.

We are excited about the potential of this collaboration and look forward to driving innovation in immunotherapy.

Der Beitrag Loma Therapeutics and Pantherna Therapeutics are pleased to announce a new collaboration aimed at accelerating the development of next-generation immunotherapies. erschien zuerst auf Pantherna Therapeutics.

Hennigsdorf, Germany 

Pantherna Therapeutics GmbH, a leading innovator in advanced LNP technologies for mRNA-based therapeutics, is pleased to announce the upcoming grant of Canadian Patent No. 3,108,670. The patent, titled “Recombinant Nucleic Acid Construct,” further strengthens the company’s global intellectual property protection.

This Canadian patent follows recent grants from the Korean, European, and Japanese patent offices. The continued expansion of Pantherna’s patent portfolio underscores the broad applicability and innovative nature of its technology for the efficient expression of therapeutic proteins.

Dr. Ansgar Santel, Chief Executive Officer of Pantherna Therapeutics, commented:
“Securing patent protection in Canada—alongside our recently granted patents in Korea, Europe, and Japan—is another significant milestone for Pantherna. These grants collectively reinforce our presence in key international markets and validate the innovative potential of our technology.”

Der Beitrag Pantherna Therapeutics Further Expands Global IP Portfolio with New Patent Grant in Canada erschien zuerst auf Pantherna Therapeutics.

Hennigsdorf, Germany 

Pantherna Therapeutics GmbH, a leader in advanced LNP technologies for mRNA-based therapeutics, is pleased to announce the grant of South Korean Patent KR 10-2811229. Issued on May 19, 2025, this new patent provides protection for the company’s proprietary PTXmRNA® technology, specifically its innovative combination of defined regulatory 5´- /3´- UTRs (untranslated regions).

This latest patent grant follows the Japanese Patent Office’s approval on April 16, 2025, underscoring the broad applicability and novelty of Pantherna’s PTXmRNA® technology for robust expression of therapeutic proteins.

Ansgar Santel, Chief Executive Officer of Pantherna Therapeutics, stated: “Securing intellectual property protection in South Korea, in addition to our recently granted Japanese patent, marks another significant milestone for Pantherna Therapeutics. These grants collectively bolster our position in key Asian markets and reinforce the global recognition of our PTXmRNA® technology’s innovative potential.”

Der Beitrag Pantherna Therapeutics Expands IP Portfolio with New Patent Grant in South Korea erschien zuerst auf Pantherna Therapeutics.

Hennigsdorf, Germany – April 16, 2025 – Pantherna Therapeutics GmbH, a company specializing in advanced LNP technologies for mRNA-based therapeutics, today announced the grant of Japanese Patent JP2021533821 by the Japan Patent Office (JPO).

Effective April 16th, the patent, titled “Recombinant nucleic acid construct”, protects a key innovation involving the company’s proprietary PTXmRNA® technology and its defined regulatory untranslated regions (5´- /3´- UTRs).

Extensive in vitro and in vivo evidence strongly support PTXmRNA’s effective and useful application across all tissues and cell types, underscoring the strength and versatility of this technology.

Ansgar Santel, Chief Executive Officer of Pantherna Therapeutics, commented on the recent patent approval: “We welcome the Japanese Patent Office’s recognition of our commitment to innovation. This patent further solidifies our standing within Japan, a key market for biotech innovation, and enhances our ability to pursue strategic partnerships and licensing opportunities in the mRNA therapeutics landscape.”

Der Beitrag Pantherna Therapeutics Secures Japanese Patent for PTXmRNA® Technology erschien zuerst auf Pantherna Therapeutics.

PRESS RELEASE

Der Beitrag Pantherna Therapeutics and TQ Therapeutics announce research collaboration to advance ultra-short Cell and Gene Therapy (CGT) process leveraging LNP technology erschien zuerst auf Pantherna Therapeutics.